KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Assets Average (2018 - 2025)

Historic Assets Average for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $355.6 million.

  • Esperion Therapeutics' Assets Average rose 670.31% to $355.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.6 million, marking a year-over-year increase of 670.31%. This contributed to the annual value of $274.8 million for FY2024, which is 2113.17% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Assets Average of $355.6 million as of Q3 2025, which was up 670.31% from $335.6 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Assets Average ranged from a high of $362.7 million in Q2 2024 and a low of $213.6 million during Q4 2023
  • Its 5-year average for Assets Average is $300.0 million, with a median of $308.4 million in 2022.
  • In the last 5 years, Esperion Therapeutics' Assets Average surged by 6033.54% in 2021 and then tumbled by 3101.49% in 2023.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Assets Average stood at $303.4 million in 2021, then decreased by 7.59% to $280.4 million in 2022, then decreased by 23.84% to $213.6 million in 2023, then soared by 54.05% to $329.0 million in 2024, then grew by 8.08% to $355.6 million in 2025.
  • Its last three reported values are $355.6 million in Q3 2025, $335.6 million for Q2 2025, and $333.9 million during Q1 2025.